SCHEMBL20178692

SCHEMBL20178692

CC(S)N1Cc2cccc(-c3cccnc3)c2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 5/20 0.44
CYP11B2 P19099 4/20 0.44
DHPS P49366 2/20 0.42
CYP19A1 P11511 2/20 0.40
CYP17A1 P05093 1/20 0.40
CYP3A4 P08684 3/20 0.38
CYP2D6 P10635 2/20 0.38
CYP2A6 P11509 2/20 0.38
CYP2E1 P05181 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2B6 P20813 1/20 0.38
CYP2C19 P33261 1/20 0.38
MAP3K5 Q99683 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 2/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ADRA2A P08913 2/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20173784 0.89 CYP11B1 (0.46) CYP11B1CYP11B2DHPSCYP19A1CYP17A1
SCHEMBL20178651 0.79 CYP11B1 (0.49) CYP11B1CYP11B2DHPSCYP19A1CYP17A1
SCHEMBL21882626 0.76 CYP11B2 (0.49) CYP11B1CYP11B2DHPSCYP19A1CYP17A1
SCHEMBL20178663 0.76 CYP11B1 (0.52) CYP11B1CYP11B2CYP19A1CYP17A1CYP3A4
SCHEMBL21882588 0.74 DHPS (0.43) CYP11B1CYP11B2DHPSCYP19A1CYP17A1
SCHEMBL23640835 0.71 CYP11B1 (0.56) CYP11B1CYP11B2DHPSCYP19A1CYP17A1
SCHEMBL21217003 0.69 SIGMAR1 (0.39)
SCHEMBL31498305 0.68 CYP11B1 (0.52) CYP11B1CYP11B2DHPSCYP19A1CYP17A1
SCHEMBL20178634 0.67 MEN1 (0.52) CYP2D6ALDH1A1TSHR
SCHEMBL21882589 0.66 ACACB (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 CYP11B1 268/4885CYP11B2 336/4885DHPS 1892/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 CYP11B1 268/4885CYP11B2 336/4885DHPS 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.